research medical center oncology

Sarah Cannon Center at Research Medical Center – Oncology 2316 East Meyer Blvd 1 West Kansas City, MO 64132

Dr Shajadi Patan

Craigin Shimmens, FNP-C,MSN

Dr. Jaswinder Singh, MD

Dr. Kiron Nair, MD

Dr. Nicholas Shuler, DO

Becky Kellam, FNP

Brandi Samson, NP

Katherine Collins, DNP, NP-C

Moeid Riaz, FNP-C

Hospital and services overview.

Radiation oncology, also called radiotherapy or radiation therapy, involves treating cancer with beams of high-energy radiation. You may be familiar with the use of radiation in the form of diagnostic chest X-rays, computerized tomography (CT) scans or dental X-rays. Radiation therapy relies on much higher X-ray energy delivered at many more times the amount of a regular X-ray in order to treat cancer.

Sarah Cannon Research Medical Center hospitals perform radiation therapy during your cancer treatment for different reasons, including:

• Neoadjuvant therapy (before surgery, to shrink a cancerous tumor)
• During surgery, to direct large doses of radiation directly at a tumor
• Adjuvant therapy (after surgery, to stop the growth of any remaining cancer cells)
• In combination with other treatments, such as chemotherapy
• Palliative care (decrease pressure or pain that the tumor puts on you)

Send A Message to MACCSP

• Patients + Families
• Healthcare Professionals
• Research + Education
• Find a Doctor
• Maps + Directions
• CANCER ANSWERLINE
• U-M Patient Log-In
• UofMHealth.org
• U-M Medical School
• Rogel INTRANET
• About Us Home
• Facts and Figures
• Clinical Care
• Support Services
• Research Programs
• Cancer Answer Line
• Community Outreach
• Cancer Registry
• National Advisory Board
• Patient and Family Advisory Committee
• Accreditations and Designations

Why support research at the University of Michigan Rogel Cancer Center?

Cancer research is an investment in a healthier future. Every dollar devoted to scientific research has the potential to transform the cancer landscape for today's patients as well as tomorrow's.

Although large-scale publicly funded research is essential to advancing medical science, it is private donors who are responsible for planting the seeds of discovery. No institution is more successful in obtaining federal grant funding for cancer research than Michigan. What's behind that success rate? Private donor support. The reality of research funding is that, before even one grant dollar is awarded, investigators need to conduct preliminary studies to confirm that the ideas they are pursuing have merit. That "seed money" comes from private philanthropy. Our track record in leveraging private gifts into grants speaks for itself: on average, one dollar of private support for U-M cancer research generates $20 in grant funding. Learn how your gift can generate this impressive return on investment.

The University of Michigan Rogel Cancer Center has a distinguished history of scientific excellence, collaboration and impact in basic science, clinical research and cancer control research. Through our focus on team science and research excellence, we aim to be a national leader in prevention, early diagnosis, optimal treatment and survivorship care for those at risk of or affected by cancer. Our mission is to reduce cancer burden and improve cancer outcomes through research, innovation, collaboration, education, outreach and engagement.

Collaboration Leads to Scientific Breakthroughs

Our members, including clinicians, researchers and other scientists, maintain a very collaborative relationship across all areas of the University of Michigan Rogel Cancer Center. Encompassing members from 53 departments across 9 University of Michigan schools, we are harnessing the power of one of the largest, most robust and highly esteemed research universities in the world to create new knowledge about cancer.

Our Research Portfolio

Cancer control and population sciences, translational and clinical research, basic science division.

Updated 11.2020

Return to top

Choose a Section:

• Patient Care
• Career Opportunities
• Ways to Donate
• Advocacy Information
• I’m just browsing
• (888) 584-7888
• Pay My Bill
• Make a Gift
• Our Hospitals
• For Patients
• For Healthcare Providers
• Clinical Trials
• Find a Service or Specialty
• The Oncology Institute and Cancer Research Program...
• Counseling and Support
• Gynecologic Oncology
• Medical and Hematology Oncology
• Oncology Institute and Cancer Research Program at Loyola
• Pediatric Cancer
• Prevention and Screenings
• Research & Clinical Trials
• Second Opinions

The Oncology Institute and Cancer Research Program at Loyola

• Types of Clinical Trials

Groundbreaking Cancer Research and Clinical Trials

The Oncology Institute at Loyola Medicine is recognized for its integrative approach to the research and implementation of cutting-edge cancer treatments and therapies.

Created as part of the Loyola University Chicago Stritch School of Medicine , the Oncology Institute is designed to provide structure to the development of a truly multidisciplinary cancer research and clinical trial program.

Whether you have been diagnosed with cancer for the first time, or are a recurrent cancer patient, Loyola offers you the opportunity for new, innovative cancer treatment options.

As a nationally recognized academic medical center, Loyola has access to cutting-edge drugs and cancer therapies that are not available at many other hospitals and cancer treatment centers.

Our priority is to find the optimal way to treat you, improve your quality of life and increase the cure rates of our cancer patients.

Why Choose Loyola for Cancer Research and Clinical Trials?

Loyola’s highly skilled clinical researchers lead and develop major national studies that directly influence the prevention of disease, course of treatment, survival and quality of life. We are committed to a multidisciplinary, integrated approach for all of our cancer services.

Loyola is proud to offer specialized cancer research programs, including:

• Breast cancer research program
• Breast clinical research program
• Breast preclinical research program
• Gastrointestinal oncology research program

Loyola’s cancer team also boasts a unique collaboration with its oncology pharmacists, who ensure the safe and effective delivery of life-saving chemotherapy  and supportive care therapies to patients.

The pharmacy staff plays an active role in the education of patients and healthcare staff on the appropriate use of medication for the treatment of cancer.

Other pharmaceutical care services offered to patients include drug interaction screening, drug use monitoring and collaboration with medical and nursing staff in clinical research programs.

Clinical Trials Benefit Future Cancer Treatments

The cancer therapies used at Loyola today are made possible by patients who volunteer to help researchers find them. Clinical trials help us find new and advanced ways to treat cancer and other diseases and improve survival rates.

Loyola offers you the opportunity to volunteer for clinical trials that involve the investigation of new treatment strategies and therapies that may include one or a combination of the following:

• Bone marrow transplant
• Chemotherapy
• Immune therapy
• Radiation therapy
• Surgical therapy

All of the clinical trials at Loyola go through two levels of internal review before being offered to patients. Loyola’s investigators in clinical cancer research have participated in more than 200 studies since 1995 in the areas of:

• Brain cancer
• Breast cancer
• Colorectal cancer
• Gastrointestinal cancer
• Genitourinary cancers
• Gynecologic cancers
• Head and neck cancer
• Lung cancer
• Multiple myeloma
• Non-Hodgkin lymphoma

Find a complete list of our current clinical trials and learn how to participate in the future of cancer research.

Request an Appointment

At Loyola, we provide the most advanced cancer treatments available, using the latest research and advanced technology to help treat body, mind and spirit. Request an appointment today with a Loyola Medicine cancer specialist.

Call Us at (888) 584-7888

Online Scheduling

Schedule a Telehealth Appointment

• Make an Appointment
• Emergency Information
• Billing, Finances & Records
• Prescriptions & Refills
• Refer a Patient
• Contact Us / Location
• Patient Rights & Responsibilities
• COVID-19 Updates
• Comprehensive Care
• Treatment Options
• Cancer Care Teams
• Help During Treatment
• Patient Support
• About Clinical Trials
• Search Clinical Trials
• Clinical Research Office
• Research & Resources

UNMCCC Programs

• Shared Resources
• Clinical Research
• Outreach & Engagement
• Center for HPV Prevention
• Investigator Tools

Research Programs

The UNM Cancer Center’s team of more than 102 researchers is making significant progress in developing new cancer drugs, genome sequencing, cancer prevention and cell signaling.

Supported by our Cancer Center Support Grant (P30CA118100), our scientists are clustered into three National Cancer Institute (NCI) research programs

surveillance, epidemiology, population genetics, anthropology, and more across the cancer continuum

Focus on cellular and molecular mechanisms that govern tumor initiation and drive cancer progression

driving the discovery, targeting, and translation of innovative breakthroughs from UNMCCC science

Collaborating for Greater Impact

New Mexico is rich with scientific and technological capabilities. Our researchers take advantage of the nearby resources by combining regional scientific strengths into our programs. UNM Cancer Center investigators regularly collaborate with scientists from our consortium partners,   Sandia National Laboratories ,   Los Alamos National Laboratory , and   Lovelace Respiratory Research Institute ; and with scientists at   New Mexico State University . These collaborations provide important insights and help to unlock some of cancer's most challenging questions.

Native American Cancer Data Website

Center for HPV Prevention (CHPVP)

National Cancer Institute - Cancer.gov

Medical Oncology Referral Office

This application  is the  first step in a multi-step process  for being considered for participation in a clinical trial at the Center for Cancer Research, National Cancer Institute at the NIH Clinical Center in Bethesda, MD. If you have any questions or have an issue filling out this form, please contact our team at 1-888-624-1937 or  [email protected] .

Research at Vanderbilt-Ingram Cancer Center

Tomorrow's cancer treatments and prevention strategies often begin in the labs of Vanderbilt-Ingram Cancer Center researchers.  Our members are dedicated to working together as a team to discover new approaches for the diagnosis, prevention, and treatment of cancer.

Research Programs

Vanderbilt-Ingram Cancer Center's eight formal research programs focus on the discovery of new approaches for the diagnosis, prevention, and treatment of cancer. These active and collaborative research programs generate approximately $142 million in annual research support from public and private sources.

More than 300 members from across Vanderbilt, the Veterans Administration Medical Center, Meharry Medical College, and Tennessee State University participate in these programs, as well as our many other cancer-focused research centers and initiatives. 

Breast Cancer

Cancer cell biology, cancer epidemiology, cancer health outcomes & control, gastrointestinal cancer, genome maintenance, host-tumor interactions, translational research & interventional oncology, specialized programs of research excellence.

The National Cancer Institute’s Specialized Programs of Research Excellence (SPOREs) grants promote and speed up the exchange between interdisciplinary research in the laboratory to the treatment of patients in the clinical care setting. SPORE programs allow laboratory and clinical scientists to work collaboratively to plan, design, and implement research programs with the greatest potential to impact cancer prevention, detection, diagnosis and treatment.

Vanderbilt-Ingram Cancer Center holds two NCI SPORE grants supporting research in gastrointestinal (GI) and breast cancers.

SPORE in Breast Cancer

Spore in gi cancer, collaborative research.

In addition to our formal research programs and SPORE grants, Vanderbilt-Ingram is home to several major epidemiologic cohort studies and a number of interdisciplinary, translational research initiatives.

• Early Detection and Cancer Prevention
• Health Disparities
• Hereditary Cancer Program
• Meharry-Vanderbilt-Tennessee State Cancer Partnership
• Shanghai Women's Health Study
• Shanghai Men's Health Study
• Southern Community Cohort Study

Vanderbilt-Ingram supports a number of institutional shared resources that provide investigators access to cutting edge technologies that are impractical to set up in individual laboratories. In addition to providing cancer center members access to state-of-the-art instrumentation and methodology, the shared resources facilitate education and technology transfer by holding workshops for members and other Vanderbilt faculty.

The Animal and Human Imaging Shared Resource (AHISR) provides scientific and technical assistance for experiments employing biomedical imaging for the study of cancer. Using this Shared Resource, Vanderbilt-Ingram Cancer Center investigators execute high throughput, quantitative and noninvasive in vivo imaging studies on animal models, apply and validate MRI, optical, CT, PET, SPECT and ultrasound methods for noninvasive detection and characterization in small animals, and incorporate emerging and clinically relevant quantitative MRI and PET protocols into Phase I, II and III clinical trials. The AHISR brings together advanced equipment and diverse expertise into a comprehensive integrated resource that ensures the quality of the imaging data, and consequently, that the overall quality, rigor, and reproducibility of the studies is the highest possible.

For more information on imaging services and prices, visit:

• Small Animal Imaging
• Human Imaging
• Computational Imaging
• Radiochemistry

The Bioanalytics and Proteomics Shared Resources (BPSR) provides cost-effective, state-of-the-art instrumentation and analytical expertise in mass spectrometry to Vanderbilt-Ingram Cancer Center investigators. The BPSR is centrally located on the Vanderbilt campus and is composed of three components that provide the following services: 1) drug and metabolomics analysis, 2) comprehensive proteomics analysis and 3) molecular profiling and tissue imaging. BPSR staff provide education and training in sample preparation, instrument-based experiments and data analysis to investigators and laboratory personnel and collaborates with cancer center investigators to continue offering the latest cutting-edge technology and methods in biomolecular mass spectrometry analysis for high-impact cancer discovery.

For information on the:

• Mass Spectrometry Core
• Proteomics Core
• Tissue Protein/Profiling Core

The Cell Imaging Shared Resource (CISR) provides access to cutting-edge technology and expert technical support for microscopic observation and analysis of tissue and cellular anatomy and physiology essential to modern cancer research. The CISR maintains the full range of advanced light and electron microscopy and digital imaging capabilities fundamental to current cancer research methodology. Through this Shared Resource, Vanderbilt-Ingram Cancer Center investigators obtain both significant cost advantages and vital access to a large array of valuable, advanced instrumentation and dedicated expertise, thus enabling and accelerating cancer research that would otherwise be reduced in quantity and quality. The expert staff in the CISR also ensures that trainees learn best practices for handling microscopes and for acquiring the best images possible in a quantitative and rigorous manner that is reproducible.

For information on CISR services provided and scheduling, visit: 

• Cell Imaging Shared Resource  

The Vanderbilt Chemical Synthesis and High-throughput Analytics Shared Resource (CSHTASR) provides state-of-the-art capabilities for the Vanderbilt-Ingram Cancer Center researchers, and works to harness the power of chemistry and assay technologies to support research requiring the application or discovery of chemical tools to answer biological questions. The CSHTASR provides a full range of services, from utilization of equipment and pilot assay development, to a full screen including hit validation/optimization. The combined technologies have revolutionized the process of drug and biological probe discovery used for the development of clinically useful therapeutics and diagnostics and for advancing basic biology and determining the functional roles of novel genes, proteins and signaling molecules. 

More information on the: 

• Chemical Synthesis Core
• High Throughput Screening Core

The mission of the Data Science Shared Resource (DSSR) is to provide professional expertise in biostatistics, bioinformatics and clinical research informatics for all Vanderbilt-Ingram Cancer Center investigators. Functions provided by the DSSR include:

• Development of experimental designs, power and sample size analysis
• Data acquisition and database development
• Facilitation of data sharing
• Patient identification within the electronic health record (EHR)
• Statistical and bioinformatics analysis and interpretation of findings
• Collaboration on presentation of results
• Education in biostatistics and bioinformatics methods
• Development of tools/methods with application to laboratory and clinical research

For information on services provided by the DSSR, visit: 

• Center for Quantitative Sciences
• Biostatistics Clinic
• VICTR Homepage

The Flow Cytometry Shared Resource (FCSR) supports the goals of the Vanderbilt-Ingram Cancer Center by providing state-of-the-art equipment and expertise to analyze and sort individual cells for cancer center members. The FCSR works closely with cancer center members to efficiently develop and refine their experiments involving flow cytometry on cancer-related samples. The overall strategy and goals of the FCSR are guided and developed to meet the needs of the cancer center members, specifically as a major user component and scientific catalyst at Vanderbilt. The FCSR occupies a modern facility with custom equipment capable of polychromatic analytical flow cytometry, high-speed sorting with aerosol containment, a new spectral cytometer for high-content analysis and a schedule with expanded access for research work when needed.

For information on scheduling, fees, training, and services provided by the FCSR, visit: 

• Flow Cytometry Shared Resource

David K. Flaherty Managing Director [email protected] 615-343-8323

Vanderbilt Genome Editing Resource (VGER) utilizes established procedures for the generation of genetically-altered mice for Vanderbilt-Ingram Cancer Center researchers. VGER performs comprehensive genome-editing mouse model creation including project design, pre-injection reagent validation, microinjection into zygotes, post-injection analysis of founder pups and breeding of the first generation to provide the investigator with validated heterozygous mice. VGER also performs state-of-the-art protocols for cryopreservation, long-term storage and distribution of mouse lines. Additional services include the resuscitation of mouse models through in vitro fertilization (IVF) and embryo transfer to restore or derive mouse lines. Moreover, the Vanderbilt Cryopreserved Mouse Repository (VCMR) is an onsite collection of cryopreserved mouse models available for rederivation or shipment.

For information on scheduling, fees, and services provided by the VGER, visit: 

• Vanderbilt Genome Editing Resource
• Vanderbilt Cryopreserved Mouse Repository

The mission of the Genomic Sciences Shared Resource (GSSR) is to bring new and powerful genomics approaches to Vanderbilt-Ingram Cancer Center researchers. To support investigators with their important work, the GSSR offers high level scientific concierge support. This includes advice on appropriate technology, sample collection, processing and extraction, biobanking and storage, and quality assessment. The GSSR offers project management and study design to protect sample and data integrity, data management and analysis. The GSSR staff are particularly well suited to facilitating good experimental design and validated methods, providing authentication services for key biological resources and in defining and establishing rigorous methods for acquiring and analyzing genomic datasets.

For information on scheduling and services provided by the GSSR, visit: 

• Next-Generation Sequencing

The mission of the Immunophenotyping Shared Resource (IPSR) is to advance immuno-oncological translational research projects by providing a rigorous platform to drive and manage comprehensive immunophenotyping, assess the immunological impact of anti-cancer therapy and deepen mechanistic understanding of cancer immunology. With its experience in immunophenotyping, immuno-oncology, antibody technologies, and biospecimen handling, the IPSR provides cost-effective and timely services to cancer center investigators.

For information on assistance with managing and facilitating pre-clinical and clinical trial laboratory studies, visit: 

• Innovative Translational Research Shared Resource

The Survey and Biospecimen Shared Resource (SBSR) provides high-quality survey and laboratory services to support Vanderbilt-Ingram Cancer Center investigators conducting population-based research, as well as “wet lab” capabilities for investigators without these facilities. Through the implementation and sharing of best practices, the SBSR staff demonstrates to users the effectiveness of a rigorous approach to the conduct of population-based research, which enables individual investigators, students, fellows and staff to better incorporate these practices into their research programs.

More information on

• Survey research services
• Biospecimen laboratory services

The Translational Pathology Shared Resource (TPSR) provides Vanderbilt-Ingram Cancer Center investigators with a full range of pathology services and technologies. The TPSR capitalizes on Vanderbilt expertise, bringing together key components to provide a comprehensive array cancer tissue services for cancer center investigators including research histology, veterinary and human pathology expertise, tissue acquisition and digital histology to support all aspects of cancer research related to the analysis of human and animal tissue specimens, and thus facilitate leading cancer discovery.

For information on pricing, training and services provided by the TPSR, visit: 

• Translational Pathology Shared Resource 

Membership and Pilot Funding 

Learn about the benefits and criteria for membership –  and pilot funding opportunities to support exciting research initiatives by new or established faculty.

Interested in becoming a cancer center member? Learn more about the types and benefits membership.

Have an exciting new research idea and looking for funding? Explore our pilot funding opportunities. 

Research Advocacy

Cancer survivors and caregivers provide a unique perspective and play an important role in helping researchers bring the best science to those affected by cancer.  The Research Advocacy program provides opportunities for advocates to participate and contribute to the research process and outcomes for future patients. 

• Meet The Advocates
• Request A Research Advocate

Seminars & Events

Vanderbilt-Ingram sponsors a very active  Seminar Program , including endowed lectures and minisymposia held throughout the year.  Through the annual Orrin Ingram Distinguished Lectureship series, distinguished extramural investigators present research discoveries that have been seminal to major advances in cancer diagnosis, prevention, treatment, and contribute to our understanding of the mechanisms of tumorigenesis.

In addition, our Annual Scientific Retreat  brings together students, postdocs, fellows and principal investigators from across the cancer center for a minisymposium, shared resource displays, and a poster session. Extramural scientists deliver lectures in the minisymposium and serve as judges for prizes given to students, postdocs, and fellows at the poster session.

VICC Seminar Series

Vicc annual scientific retreat, research news.

Researchers develop new nanoparticle to boost immune system

Vanderbilt nanodrug may be a paradigm shift for cancer.

VUMC to help engage more study participants in research decisions

Human research will be more equitable, inclusive and stronger if the people who are participants in studies also help plan and guide the direction of those studies.

Questions about our Research Programs ?

Contact us by email

Connect With Us

Coronavirus (COVID-19): Latest Updates | Visitation Policies Visitation Policies Visitation Policies Visitation Policies Visitation Policies | COVID-19 Testing | Vaccine Information Vaccine Information Vaccine Information

Department of Medicine

Hematology & oncology.

Our specialists work with researchers studying many aspects of cancer. Hematology/Oncology faculty are involved with all three Wilmot Cancer Institute research programs : Cancer Prevention & Control; Cancer Microenvironment; and Genetics, Epigenetics and Metabolism. Working together with researchers from other fields can bring about creative solutions to some of today’s biggest challenges in cancer.

Here are some examples of recent trials and projects:

• Studies to  better understand “polypharmacy,”  which is the concurrent use of multiple medications; it can lead to harmful drug interactions, which is especially important for cancer patients about to undergo therapy
• Work that improves  oncologist-patient communication , especially for older adults with cancer 
• Basic science and clinical research behind  an innovative treatment idea  for myelodysplastic syndrome (MDS)
• Geriatric oncology projects that focus on  personalizing cancer care for patients older than 70 , with help from geriatric assessments

Read about how our research programs and scientists are working to discover new treatments for our patients.

• WMCHealth Corporate Site
• Westchester Medical Center
• Maria Fareri Children's Hospital
• Behavioral Health Center
• Bon Secours Community Hospital
• Good Samaritan Hospital
• HealthAlliance
• Margaretville Hospital
• MidHudson Regional Hospital
• St. Anthony Community Hospital
• Advanced Physician Services
• Bon Secours Medical Group
• Audio Archive
• COVID-19 Information
• Mountainside Residential Care Center
• Schervier Pavilion
• Sexual Assault and Victim Empowerment
• Find a Provider
• Computed Tomography (CT)
• Digital X-Ray
• Image Management
• Lung Cancer Screening
• MRI (Cardiac)
• Musculoskeletal Imaging
• Neuroradiology Imaging
• Nuclear Medicine
• Pediatric Radiology
• PET/CT Center
• Vascular and Interventional Radiology
• Women's Imaging Center
• Pain Management
• Radiology Residency Program
• Make an Appointment
• Advanced Minimally Invasive Gynecologic Surgery and Pelvic Pain
• Center for Women’s Health Equity
• General Obstetrics and Gynecology
• Ovarian, Fallopian, and Primary Peritoneal
• Endometrial (Uterine Cancer)
• Cervical Cancer
• Vaginal and Vulvar Cancer
• Maternal-Fetal Medicine (Perinatology)
• Reproductive Genetics
• Urogynecology, Female Pelvic Medicine and Reconstructive Surgery
• Anesthesiology Residency Program
• Bariatric and Minimally Invasive Surgery
• Bone Marrow Transplant
• Neurocritical Care Fellowship
• Neuromuscular Disease
• Spine Care Program
• Peripheral Nerve Program
• Neurosurgical Oncology and Skull Base Surgery
• Stroke Care
• Pediatric Neurosurgery
• Pediatric Epilepsy Surgery Program
• Functional Neurosurgery and Adult Epilepsy Surgery Program
• Neurosurgery Residency Program
• CNS Endovascular Fellowship
• Contact Brain and Spine Institute
• Breast Surgery
• Burn Center
• Aortic Aneurysm Surgery
• Coronary Bypass Surgery
• Heart Transplant and Heart Failure
• Hypertrophic Cardiomyopathy Program (HCM)
• Mechanical Circulatory Support | Ventricular Assist Device (VAD)
• Pediatric Cardiothoracic Surgery
• Thoracic Surgery
• Transcatheter Valve Program
• Valve Surgery
• Patient Stories
• Cochlear Connections Newsletter
• Our Research
• Colorectal Surgery
• Care for Families and Patients
• Westchester Medical Center COVID-19 Testing
• WMCHealth Post-COVID-19 Recovery Program
• Department of Medicine
• Dermatology
• Download a Referral Form
• Balance Issues
• Balance Testing and Therapy
• Balance Testing and Therapy: Vestibular and Balance Therapy
• Balance Testing and Therapy: Videonystagmography
• Cochlear Implant Center
• Ear Conditions and Diagnoses
• Ear Surgeries and Procedures
• Ear, Nose and Throat (ENT) Care for Children
• Hearing Loss Conditions and Diagnoses
• Hearing Solutions and Treatments
• Mouth Conditions and Diagnoses
• Nasal Conditions and Diagnoses
• Nasal Surgeries and Procedures
• Neck Conditions and Diagnoses
• Neck Surgeries and Procedures
• Skull Base Surgery
• Skull Base Tumors
• Throat Conditions and Diagnoses
• Throat Surgeries and Procedures
• Voice and Swallowing Program
• e-Health Program
• Emergency Medicine
• Endocrinology and Metabolism
• Flu Vaccine and COVID-19 Booster Shots
• Flu Vaccine Appointments and Screening
• Forensic Acute Care Team (FACT)
• Gastroenterology
• General Surgery
• Gynecologic Oncology
• What-to-Expect
• Headache Procedures
• Headaches and Chronic Pain
• Headache Surgery
• Headache Forms
• Angiograms and Catheterizations
• Angioplasty, Stenting, Atherectomy
• Atrial Septal Defects & PFO
• Balloon Valvuloplasty
• Cardiac Catheterization and Invasive Cardiology
• Cardiac CT Scan
• Cardiac Electrophysiology
• Cardiac Genetic Testing
• About the Director
• Cardiopulmonary Exercise Testing (CPEX)
• Cartoid and Peripheral Arterial Disease
• Catheter Ablation for Cardiac Arrhythmias
• Congenital Heart Disease
• How an Echocardiogram is Performed
• Electrocardiography
• Fractional Flow Reserve
• Medical Management
• Rhythm Management
• Heart Transplant Program
• Holter Monitoring
• Mechanical Circulatory Support
• Nuclear Imaging (Cardiac SPECT, MUGA)
• Pulmonary Hypertension
• Radiofrequency Ablation
• Stress Testing
• Tilt Testing
• Ventricular Assist Devices
• Cardiothoracic Surgery
• Same-Day Cardiology Program
• Vascular Surgery
• Hyperbaric Medicine
• Infectious Diseases
• Integrated Wound Care
• Internal Medicine
• Laboratory Services
• Monkeypox Vaccine
• Memory Disorders Program
• Neurosurgery
• Occupational Health Center
• Ophthalmology
• Musculoskeletal Oncology
• Sports Medicine
• Pediatric Orthopaedics
• Spine and Scoliosis
• Joint Replacement Surgery
• The Ally Care Center
• Palliative Care
• Pediatric Hematology/Oncology
• Advanced Imaging Center
• Advanced OB-GYN Associates
• Brain and Spine Institute | Department of Neurosurgery
• Cosmetic Center
• COVID-19: Vaccination, Testing and Treatment
• Ear, Nose and Throat (ENT) / Otolaryngology
• Heart and Vascular Institute
• Orthopaedics / Orthopaedic Surgery
• Pediatric Services
• Psychiatry / Mental Health
• Transplant Center
• Trauma Center
• Vein Center
• Westchester Medical Center Cancer Center
• View All Services
• Pediatric Surgery
• PET / CT Center
• Plastic Surgery
• Preventive Health Screenings, Tests and Immunizations
• Children and Adolescent Psychiatry
• Consultation Liaison
• Interventional Pulmonology
• Rehabilitation Medicine
• Rheumatology
• Surgical Oncology
• Sleep Medicine
• Heart Transplant
• Kidney Transplant
• Liver Transplant
• Pediatric Liver Transplant
• National Donate Life Month
• Varicose Vein Treatment
• Breast Cancer Program
• Cardio-Oncology Program
• Cellular Therapy and Stem Cell Transplantation
• Colorectal Oncology Program
• Genitourinary Oncology
• Hematologic Malignancies (Blood Cancers)
• Pediatric Oncology
• Thoracic Oncology
• Advanced Imaging
• Interventional Oncology

Radiation Medicine

• Public Reports
• Adolescent and Young Adult (AYA) Program
• WMCHealth COVID-19 Specimen Collection for Testing
• Coronavirus: Need to Know
• WMCHealth Vaccine Information
• Women's Health
• Worksite Wellness Program
• Angiograms & Catheterizations
• Cardiac Catherterization & Invasive Cardiology
• Echocardiography
• Heart Failure
• Abdominal Aortic Aneurysm
• Aortoiliac Occlusive Disease
• Carotid Artery Disease
• Chronic Venous Disease
• Deep Vein Thrombosis (DVT)
• Diabetic Vascular Disease
• Hyperlipidemia
• Hypertension
• Peripheral Artery Disease
• Peripheral Vascular Disease
• Portal Hypertension
• Pulmonary Embolism
• Renal Failure
• Renovascular Conditions
• Thoracic Aneurysm
• Thoracic Outlet Syndrome
• Vascular Malformations
• Arteriogram
• Duplex Ultrasound
• Extremity Blood Pressure
• Magnetic Resonance Angiography
• Magnetic Resonance Imaging
• Plethysmography
• Pulse Volume Recording
• Transcranial Doppler
• Transcutaneous Oximetry
• Caregiver Center
• Clinical Research Programs
• Grateful Patients
• Guides for Patients and Families
• Insurance and Billing
• Medical Records
• Patient Experience
• Patient Information
• Patient Portal
• Patient Rights
• Pre-Procedure Information
• Spiritual Health Services
• Other Resources
• Care Champions
• DAISY Award
• Online Gift Shop
• Patient Family Advisory Councils
• Send an E-Greeting Card
• Upcoming Events
• Visiting Hours and Guidelines
• Refer/Transfer a Patient
• Clinical Trials
• Faculty Development
• Graduate Medical Education
• PGY1 Pharmacy Residency Program
• Foundations of WMCHealth
• Frequently Asked Questions
• Contact Information
• Volunteer Application

Oncology: Clinical Research Program

Oncology: Clinical Studies Open For Enrollment

Solid tumors, brain tumors, transplants, immunochemotherapy with obinutuzumab, ifosfamide, carboplatin and etoposide (o-ice) in caya with recurrent refractory cd20+ mature b-nhl, pilot study using induction chemo-immunotherapy followed by consolidation with reduced toxicity conditioning and allogenic stem cell transplant in advanced stage mature non-anaplastic t-cell or nk lymphoma/leukemia in children, adolescents and young adults; a nk/t-cell lymphoma/leukemia consortium study, aall1731, a phase 3 trial investigating blinatumomab (ind# 117467, nsc# 765986) in combination with chemotherapy in patients with newly diagnosed standard risk or down syndrome b-lymphoblastic, cirb aall1732 a phase 3 randomized trial of inotuzumab ozogamicin (ind#:133494, nsc#: 772518) for newly diagnosed high-risk b-all; risk-adapted post-induction therapy for high-risk b-all, mixed phenotype acute leukemia, and disseminated b-lly, safety and tolerability of myeloablative conditioning and autologous stem cell transplantation followed by polatuzumab vedotin (pv) immunoconjugate therapy in patients with b-cell non-hodgkin and hodgkin lymphoma, a multicenter, open-label, phase 2 study to evaluate the safety and pharmacokinetics of eflapegrastim in pediatric patients with solid tumors or lymphomas and treated with myelosuppressive chemotherapy, reducing the burden of oncologic chemoradiotherapy and radiation exposure from diagnostic imaging by utilizing targeted immunotherapy in children, adolescents and young adults with lymphoma (radical), a phase 2 open-label clinical study to evaluate the efficacy and safety of zilovertamab vedotin (mk-2140) in participants with relapsed or refractory diffuse large b-cell lymphoma (003), a phase 2/3 multicenter, open-label, randomized, active-control study of zilovertamab vedotin (mk-2140) in combination with standard of care in participants with relapsed or refractory diffuse large b-cell lymphoma. (004), anhl1931, a randomized phase 3 trial of nivolumab (nsc# 748726 ind# 125462) in combination with chemo-immunotherapy for the treatment of newly diagnosed primary mediastinal b-cell lymphoma, a phase 3 open label, randomized study of pirtobrutinib (loxo-305) versus ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (bruin-cll-314), accl1931: a randomized trial of levocarnitine prophylaxis to prevent asparaginase-associated hepatotoxicity in adolescents and young adults receiving acute lymphoblastic leukemia therapy, a phase i clinical trial to study the safety, pharmacokinetics, and efficacy of bp1002 (l-bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies, eligibility.

• Subject is between three years and 31 years of age
• In first or second relapse or primary induction failure CD20 positive B-cell leukemia/lymphoma 

Enrollment Status: Enrolling

Study Information

ClinicalTrials.gov | NCT02393157

Principal Investigator

Mitchell Cairo, MD

Contact for Study Screening

[email protected]

• Subject is between one year and 31 years of age
• Patients must weigh at least 10 kilograms at the time of the study enrollment 
• Newly diagnosed patients with histologically proven mature T- and NK- cell neoplasms

ClinicalTrials.gov | NCT03719105

Aliza Gardenswartz, MD

• Subject is between one year and 30 years of age
• Disease: B-ALL

ClinicalTrials.gov | NCT03914625

Jessica Hochberg, MD

• B-cell Lymphoblastic Leukemia
• B-cell Lymphoblastic Lymphoma
• Subject is between one month and 17 years of age
• Newly diagnosed/relapsed/recurrent solid tumor or lymphoma without bone marrow involvement
• Receiving myelosuppressive chemotherapy, with a febrile neutropenia rate of at least 20% as outlined in the National Comprehensive Cancer Network (NCCN) guidelines

ClinicalTrials.gov | NCT04570423

ClinicalTrials.gov | NCT05253495

• Subject is at least 18 years of age
• Relapsed or refractory DLBCL and is ineligible for or have failed autologous stem-cell transplant (ASCT) and have failed at least one line of prior therapy
• Has relapsed or refractory DLBCL and is ineligible for or have failed ASCT and have failed at least two lines of prior therapy

ClinicalTrials.gov | NCT05139017

• Has relapsed or refractory (rr) DLBCL
• Has progressed after at least two lines of prior therapy, and
• Has progressed after auto-stem cell transplant (SCT) or are auto-SCT ineligible
• Must have received prior multiagent regimen that includes an alkylating agent, anthracycline, and anti-CD20 (cluster of differentiation 20) monoclonal antibody

ClinicalTrials.gov | NCT05144841

• Subject is at least two years of age
• Primary mediastinal B-cell lymphoma (PMBCL)

ClinicalTrials.gov | NCT04759586

• Male or female age 18 years or older per local regulations at time of enrollment
• Confirmed diagnosis of CLL/SLL requiring therapy per iwCLL 2018 criteria
• Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
• For matched healthy controls, Adequate organ function - Platelets greater than or equal to (≥)50 x 10⁹/liter (L) or ≥30 x 10⁹/L in participants with documented bone marrow involvement considered to impair hematopoiesis, Hemoglobin ≥8 grams/deciliter (g/dL) or ≥6 g/dL in participants with documented bone marrow involvement considered to impair hematopoiesis, Absolute neutrophil count ≥0.75 x 10⁹/L or ≥0.50 × 10⁹/L in participants with documented bone marrow involvement considered to impair hematopoiesis and Kidney function: Estimated creatinine clearance ≥30 milliliters per minute (mL/min)
• Known or suspected Richter's transformation to diffuse large B-cell lymphoma (DLBCL), prolymphocytic leukemia, or Hodgkin's lymphoma at any time preceding enrollment
• Known or suspected central nervous system (CNS) involvement
• A significant history of renal, neurologic, psychiatric, endocrine, metabolic or immunologic disease
• Hepatitis B or hepatitis C testing indicating active/ongoing infection, based on Screening laboratory tests
• Active uncontrolled systemic bacterial, viral, or fungal infection
• Active cytomegalovirus (CMV) infection
• Participants with known hypersensitivity, including anaphylaxis, to any component or excipient of Pirtobrutinib or ibrutinib

ClinicalTrials.gov | NCT05254743

Delong Liu, MD

[email protected]

• Male or female at least 15 years of age
• Newly Diagnosed B-ALL, T-ALL, Lymphoblastic Lymphoma (LLy), or Mixed-Phenotype Acute Leukemia/Lymphoma (MPAL)

[email protected]

• Male or female at least 18 years of age
• Patient has a life expectancy ≥ 3 month
• Patient has relapsed or refractory disease
• ECOG Performance score of 0, 1, or 2
• Adequate hepatic and renal functions
• Recovered from the effects of any prior surgery, radiotherapy, or antineoplastic treatment (with the exception of alopecia), based on Investigator assessment.
• Exclusion Criteria: for matched healthy controls; Active non-hematologic malignancy other than hematologic malignancies treated with immuno- or chemotherapy within the previous 12 months except active non-melanoma, non-invasive skin cancer will be allowed and Patient eligible for high dose chemotherapy and autologous stem cell transplant.

ClinicalTrials.gov | NCT04072458

Karen Seiter, MD

ADVL1822: A PHASE 1/2, MULTI-CENTER, DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF QUIZARTINIB ADMINISTERED IN COMBINATION WITH RE-INDUCTION CHEMOTHERAPY, AND AS A SINGLE-AGENT CONTINUATION THERAPY, IN PEDIATRIC RELAPSED/REFRACTORY AML SUBJECTS AGED 1 MONTH TO < 18 YEARS (AND YOUNG ADULTS AGED UP TO 21 YEARS) WITH FLT3-ITD MUTATIONS

Aaml1831 cirb, a phase 3 randomized trial for patients with de novo aml comparing standard therapy including gemtuzumab ozogamicin (go) to cpx-351 with go, and the addition of the flt3 inhibitor gilteritinib for patients with flt3 mutations, aall1631, international phase 3 trial in philadelphia chromosome-positive acute lymphoblastic leukemia (ph+ all) testing imatinib in combination with two different cytotoxic chemotherapy backbones, aaml18p1, stopping tyrosine kinase inhibitors (tki) to assess treatment-free remission (tfr) in pediatric chronic myeloid leukemia - chronic phase (cml-cp), a phase 1/2 study of the safety, tolerability, pharmacokinetics, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical hodgkin lymphoma and non-hodgkin lymphoma, asct2031, a multi-center, phase 3, randomized trial of matched unrelated donor (mud) versus hlahaploidentical related (haplo) myeloablative hematopoietic cell transplantation for children, adolescents, and young adults (aya) with acute leukemia or myelodysplastic syndrome (mds).

• Subject is between one year and 21 years of age
• AML with at least 5% blasts in bone marrow, with or without extramedullary disease
• First relapse or refractory to first-line high-dose chemotherapy with no more than one attempt (one to two cycles of induction chemotherapy) at remission induction - prior HSCT is permitted

ClinicalTrials.gov | NCT03793478

• Subject is no older than 22 years of age
• Newly diagnosed with de novo AML with or without extramedullary disease
• At least 20% bone marrow blasts (obtained within 14 days prior to enrollment)
• Less than 20% bone marrow blasts with one or more of the genetic abnormalities associated with childhood/young adult AML as provided in the protocol (sample obtained within 14 days prior to enrollment)
• A complete blood count (CBC) documenting the presence of at least 1,000/uL

ClinicalTrials.gov | NCT04293562

• Subject is between two and 21 years of age
• Newly diagnosed de novo ALL (B-ALL or T-ALL) or mixed phenotypic acute leukemia with definitive evidence of BCR-ABL1 fusion by karyotype, fluorescence in situ hybridization (FISH) and/or reverse transcriptase (RT)-PCR

ClinicalTrials.gov | NCT03007147

• Subject is no older than 25 years of age
• CML-CP at original diagnosis
• Molecular remission (MR) with a BCR-ABL1 level of no more than 0.01% BCR-ABL1

ClinicalTrials.gov | NCT03817398

• Subject is 30 years of age or younger
• Recurrent or refractory Hodgkin or non-Hodgkin Lymphoma and have failed at least one line or prior therapy

ClinicalTrials.gov | NCT05255601

• Subject is 6 months to 21 years of age
• Diagnosed with ALL, AML or MDS and no sibling donor  
• Has not received a prior allogeneic hematopoietic stem cell transplant

ClinicalTrials.gov | NCT05457556

A Phase 1 Study of Vorinostat in Combination with Vincristine, Irinotecan and Temozolomide in Children, Adolescents and Young Adults with Relapsed or Refractory Solid Tumors and CNS Malignancies

Agct1531: a phase 3 study of active surveillance for low risk and a randomized trial of carboplatin vs. cisplatin for standard risk pediatric and adult patients with germ cell tumors, anbl1531 (cirb): a phase 3 study of 131i-metaiodobenzylguanidine (131i-mibg) or crizotinib added to intensive therapy for children with newly diagnosed high-risk neuroblastoma (nbl) (ind# 134379), cirb agct1532 a randomized phase 3 trial of accelerated versus standard bep chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumors, cirb aren1921, treatment of newly diagnosed diffuse anaplastic wilms tumors (dawt) and relapsed favorable histology wilms tumors (fhwt), ahep1531 pediatric hepatic malignancy international therapeutic trial (phitt).

• A PHASE 2 STUDY OF DS-8201A (NSC# 807708, IND# 153036) IN ADOLESCENTS, OR YOUNG ADULTS WITH RECURRENT HER2+ OSTEOSARCOMA PEPN1924
• CIRB,AOST2031, A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma

ACNS2031:A Phase 3 Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy in Children with Medulloblastoma with Low-Risk Features

Pepn2121: a phase 1/2 study of tiragolumab (nsc# 827799, ind# 161266) and atezolizumab (nsc# 783608, ind# 161266) in patients with relapsed or refractory smarcb1 or smarca4 deficient tumors, aost2032: a feasibility and randomized phase 2/3 study of the vefgr2/met inhibitor cabozantinib in combination with cytotoxic chemotherapy for newly diagnosed osteosarcoma.

• Subject is between 1 year and 30 years of age
• Patients must have a confirmed histologic diagnosis of a relapsed or refractory solid tumor or CNS malignancy

ClinicalTrials.gov | NCT04308330

Jeremy Rosenblum, MD

• There is no age limit for the low risk stratum (stage I ovarian immature teratoma and stage I non-seminoma or seminoma malignant GCT)
• Standard risk 1: Patient must be less than 11 years of age at enrollment
• Standard risk 2: Patients must be at least 11 and less than 25 years of age at enrollment
• Patients enrolling on one of the low risk arms must be newly diagnosed with a stage I germ cell tumor; for the standard risk arms, patients must be newly diagnosed with metastatic germ cell tumor (stage II or higher)
• Low risk stage I immature teratoma (IT); site: ovarian; stage: Children's Oncology Group (COG) stage I; grade: 2 or 3; histology: pure immature teratoma, mixed immature and mature teratoma; tumor markers: alpha-FP less than or equal to 1,000 ng/mL, beta-HCG institutional normal; all ages
• Low risk stage I non-seminoma MGCT; site: ovarian, testicular, or extragonadal; stage: COG stage I, FIGO stage IA and IB; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma (pure or mixed); all ages
• Low risk stage I seminoma-MGCT; site: testicular; stage: COG stage I; histology: must contain at least one of the following: may contain immature/mature teratoma; may NOT contain yolk sac tumor, embryonal carcinoma, or choriocarcinoma; all ages
• Standard risk 1 (SR1); site: ovarian, testicular, or extragonadal; stage: COG stage II-IV; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma; age less than 11 years
• Site: ovarian; stage: COG stage II and III; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma; age at least 11 and less than 25 years
• Site: testicular; stage: COG stage II-IV, AJCC stage II, III, IGCCC good risk; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma; tumor markers: must be IGCCC good risk; post op: alpha-FP less than 1,000 ng/mL, beta-HCG less than 5,000 IU/mL and lactate dehydrogenase (LDH) less than 3.0 x normal; age at least 11 and less than 25 years
• Site: extragonadal; stage: COG stage II; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma; age at least 11 and less than 25 years

ClinicalTrials.gov | NCT03067181

• Diagnosis of neuroblastoma or ganglioneuroblastoma (nodular) verified by tumor pathology analysis or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamine metabolites
• The following disease groups are eligible:
• MYCN amplification (greater than four-fold increase in MYCN signals as compared to reference signals), regardless of additional biologic features; or
• Age greater than 547 days regardless of biologic features
• Patients with INRG stage MS disease with MYCN amplification
• Patients with INRG stage L2 disease with MYCN amplification
• Patients greater than 547 days of age initially diagnosed with INRG stage L1, L2 or MS disease who progressed to stage M without prior chemotherapy may enroll within four weeks of progression to stage M
• Patients at least 365 days of age initially diagnosed with MYCN amplified INRG stage L1 disease who progress to stage M without systemic therapy may enroll within four weeks of progression to stage M

ClinicalTrials.gov | NCT03126916

• Subject is between 11 - 45 years of age
• Histologically or cytologically confirmed germ cell tumor (non-seminoma or seminoma), or
• Exceptionally raised tumor markers (AFP at least 1000ng/mL and/or HCG at least 5000 IU/L) without histologic or cytologic confirmation in the rare case where pattern of metastases consistent with GCT, high tumor burden, and a need to start therapy urgently
• Primary arising in testis, ovary, retro-peritoneum, or mediastinum
• Metastatic disease or non-testicular primary
• Intermediate or poor prognosis

ClinicalTrials.gov | NCT02582697

• Subject is between 1 month and 17 years of age
• Subject is no older than 30 years of age
• Newly diagnosed stages 2 - 4 diffuse anaplastic Wilms tumor 

ClinicalTrials.gov | NCT04322318

• Newly diagnosed with histologically-proven primary pediatric hepatic malignancies including hepatoblastoma or hepatocellular carcinoma

ClinicalTrials.gov | NCT03533582

A PHASE 2 STUDY OF DS-8201A (NSC# 807708, IND# 153036) IN ADOLESCENTS, OR YOUNG ADULTS WITH RECURRENT HER2+ OSTEOSARCOMA PEPN1924 

• Subject is between 12 - 39 years of age
• Osteosarcom having received at least standard initial therapy

ClinicalTrials.gov | NCT04616560

CIRB,AOST2031, A Phase 3 Randomized Controlled Trial Comparing Open vs Thuoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma 

• Subject is no older than 50 years of age
• Osteosarcoma
• Patients must have evidence of metastatic lung disease at the time of initial diagnosis, or at time of first recurrence following completion of therapy for initially localized disease
• Patients with newly diagnosed disease must have completed successful gross tumor resection for their primary tumor or surgical local control of primary tumor must be planned to be performed simultaneously with thoracic surgery

ClinicalTrials.gov | NCT05235165

• Subject is between 3 years and 22 years of age
• Must be newly diagnosed medulloblastoma

ClinicalTrials.gov | NCT05382338

• Renal medullary carcinoma
• Malignant rhabdoid tumor (extra-CNS)
• Atypical teratoid rhabdoid tumor (CNS)
• Poorly differentiated chordoma
• Epithelioid sarcoma
• Other SMARCB1 or SMARCA4 deficient tumors
• Subject must be at least 12 months of age 
• Part A, patients must be less than 18 years old
• Part B, patients must be 18 years or older

ClinicalTrials.gov | NCT05286801

• Patients must be less than 40 years of age at time of enrollment.
• Patients must have a body surface area of greater than or equal to 0.8m2 at the time of enrollment.
• Patients must have a histologic diagnosis (by institutional pathologist) of newly diagnosed high grade osteosarcoma. Primary tumors of all extremity and axial sites are eligible as long as diagnosis of high-grade osteosarcoma is established. Osteosarcoma as a second malignancy is eligible if no prior exposure to systemic chemotherapies.

ClinicalTrials.gov | NCT05691478

ACNS1422 (CIRB) A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Head start 4 protocol:  newly diagnosed children (less than 10 years old) with medulloblastoma and other central nervous system embryonal tumors. clinical and molecular risk-tailored intensive and compressed induction chemotherapy followed by consolidation with randomization to either single-cycle or to three sequential cycles of marrow-ablative chemotherapy with autologous hematopoietic progenitor cell rescue, acns1831, cirb a phase 3 randomized study of selumetinib (ind # 77782) versus carboplatin/vincristine in newly diagnosed or previously untreated neurofibromatosis type 1 (nf1) associated low-grade glioma (lgg), acns1833: a phase 3 randomized non-inferiority study of carboplatin and vincristine versus selumetinib (nsc# 748727, ind# 77782) in newly diagnosed or previously untreated low-grade glioma (lgg) not associated with brafv600e mutations or systemic neurofibromatosis type 1 (nf1), acns1931, a phase 3 study of selumetinib (nsc# 748727, ind# 77782) or selumetinib in combination with vinblastine for non-nf1, non-tsc patients with recurrent or progressive low-grade gliomas, acns2021, a phase 2 trial of chemotherapy followed by response-based whole ventricular & spinal canal irradiation (wvsci) for patients with localized non-germinomatous central nervous system germ cell tumor, a multicenter observational study of gammatile™ surgically targeted radiation therapy (start) in intracranial brain neoplasms.

• 1 month - 17 years of age at time of study entry
• Has a pathologic/histologic confirmed newly diagnosed/relapsed/recurrent solid tumor or lymphoma without bone marrow involvement 
• Is a candidate to receive myelosuppressive chemotherapy

Enrollment Status: Actively enrolling

Mitchell S. Cairo, MD

• Subject is between 3 years and 21 years of age
• Classical histologic type (non LC/A) WNT medulloblastoma that is Positive nuclear beta-catenin by immunohistochemistry (IHC), Positive for CTNNB1 mutation and Negative for MYC and MYCN by fluorescence in situ hybridization (FISH); negative CNS on lumbar puncture

ClinicalTrials.gov | NCT02724579

• Subject is no more than 10 years of age
• Diagnosis of medulloblastoma or CNS embryonal tumors of the brain or spinal cord

ClinicalTrials.gov | NCT02875314

• Subject is between 2 and 21 years of age
• Neurofibromatosis type 1 (NF1)
• Newly diagnosed or have previously diagnosed NF-1 associated LGG that has not been treated with any modality other than surgery
• Optic pathway gliomas

ClinicalTrials.gov | NCT03871257

• Non-neurofibromatosis type 1 (non-NF1) low-grade glioma (LGG) without a BRAFV600E mutation
• All tumors considered low-grade glioma or low-grade astrocytoma

ClinicalTrials.gov | NCT04166409

• Subject is between 2 and 25 years of age
• Non-neurofibromatosis type 1 (non-NF1), non-tuberous sclerosis complex (non-TSC) low-grade glioma (LGG) without a BRAFV600E or IDH1 mutation
• Progressive or recurrent LGG
• Metastatic disease or multiple independent primary LGGsl

ClinicalTrials.gov | NCT04576117

• Subject is between 3 and 30 years of age
• Newly diagnosed with localized primary CNS NGGCT of the suprasellar and/or pineal region by pathology and/or serum or cerebrospinal fluid (CSF) elevation of AFP above institutional normal or greater than 10 ng/mL or human chorionic gonadotropin (hCG) beta greater than 100 mIU/mL
• Suprasellar, pineal and bifocal tumors are included
• Patients with any of the following pathological elements are eligible: endodermal sinus (yolk sac), embryonal carcinoma, choriocarcinoma, malignant/immature teratoma and mixed germ cell tumor (GCT) (i.e., may include some pure germinoma) if malignant elements listed above are present

ClinicalTrials.gov | NCT04684368

• Patients who undergo maximum safe resection of intracranial neoplasm(s) AND implantation of GammaTiles
• Willing and able to provide informed consent and to participate in all evaluations

ClinicalTrials.gov | NCT04427384

Simon Hanft, MD

[email protected]

A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma Protocol GOG 3065/ZN-c3-004

A phase 3, multicenter, open-label, randomized study of nemvaleukin alfa in combination with pembrolizumab versus investigator’s choice chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (artistry-7), nrg gy-019- a randomized phase iii, two-arm trial of paclitaxel/carboplatin/maintenance letrozole versus letrozole monotherapy in patients with stage ii-iv, primary low-grade serous carcinoma of the ovary or peritoneum, nrg-gy018- a phase 3 randomized, placebo-controlled study of pembrolizumab (mk-3475) in addition to paclitaxel and carboplatin for measurable stage iii or iva, stage ivb or recurrent endometrial cancer, a phase 2 open-label, multicenter study to evaluate efficacy and safety of zn-c3 in subjects with malignant tumors harboring dna repair and cell cycle gene alterations, a two-stage, randomized, controlled trial comparing the safety and efficacy of iltamiocel with placebo in the treatment of female participants with chronic fecal incontinence and a history of obstetric anal sphincter injury (dignifi).

• Females at least 18 years of age at the time of informed consent
• Recurrent or persistent Uterine Serous Carcinoma
• Measurable disease
• Treatment with at least one prior platinum-based chemotherapy regimen for management of advanced or metastatic USC

ClinicalTrials.gov | NCT05683691

EudraCT 2020-005172-35

Tana Pradhan, MD

[email protected]

• Confirmed ovarian cancer (high-grade serous, endometrioid, clear cell, fallopian tube cancer or primary peritoneal cancer
• At least 18 years of age
• Patient must have received at least one prior line of systemic anticancer therapy
• Patient must have received bevacizumab
• Patient must have had PARP inhibitor therapy if BRCA mutation exists
• Disease progression
• Patient NO requires or has NOT taken systemic corticosteroids

ClinicalTrials.gov | NCT05092360

• Patients must have newly diagnosed, Stage II-IV low-grade serous ovarian cancer
• Patients must be able to take oral medications
• Patients may not have received previous hormonal therapy for the treatment of this disease
• Patients with NO central nervous system metastases

ClinicalTrials.gov | NCT04095364

• Diagnosis of endometrial cancer
• Measurable stage III, measurable stage IVA, stage IVB, or recurrent endometrial cancer
• Must have a measurable lesion on CT or MRI scan

ClinicalTrials.gov | NCT03914612

• Locally advanced or metastatic malignancy
• Solid tumor with one or more relevant genetic alterations in DDR-related genes. These are defined as pathogenic (deleterious) mutations in the MRN complex genes (MRE11, RAD50, or NBN) or CCNE1 amplifications
• Must have received prior standard therapy appropriate for their tumor type and stage of disease
• Must have at least one measurable lesion
• No major surgery within 28 days (any surgical incision should be fully healed prior to study drug administration)

ClinicalTrials.gov | NCT04158336

• Adult female at least18 years of age who has primary symptoms of FI for at least 12 months as confirmed by medical history and presents with ≥4 uncontrolled passages of solid or liquid stool as recorded in a 14-Day Diary at Screening.
• Has a history of obstetric anal sphincter injury (e.g., episiotomy, perineal tear) as confirmed by participant’s medical records and/or endoanal ultrasound.
• Failed conservative treatment (e.g., dietary modification, antidiarrheal medications, pelvic floor muscle training, biofeedback) for at least 6 months prior to enrollment.
• Has a Cleveland Clinic Florida Incontinence Score (CCFIS) ≥9 at Baseline.
• For the duration of study participation, must be willing and able to comply with the study procedures, be mentally competent and able to understand all study requirements, and must agree to read and sign the informed consent form prior to any study-related procedures.
• Simultaneously participating in another investigational drug or device study or has completed the follow-up phase for the primary endpoint of any previous study less than 30 days prior to the first evaluation in this study.
• Is pregnant or planning to become pregnant within the next 2 years.
• Has an implanted stimulation neuromodulation system (sacral or tibial) and symptoms are unstable as determined by the physician.
• Has received injection of a bulking agent within 1-year prior to the first evaluation in the study.
• Has known rectal sensory dysfunction (e.g., hypersensitivity or hyposensitivity).
• Any cancer that has undergone treatment within the past 12 months.

ClinicalTrials.gov | NCT05776277

Cara Grimes, MD

[email protected]

Prospective, multi-center single arm study of vanquish water vapor ablation for prostate cancer

• Male at least 50 years of age
• 20-80 cc prostate size determined by MRI Central Imaging
• ≤15 ng/ml PSA
• Cancer stage less than or equal to T2c
• Within 12 months prior to signing consent have had a multiparametric MRI. Within 6 months prior to signing consent, have undergone a multiparametric MRI software guided fusion biopsy of the prostate (transrectal or transperineal). This must include a standard sector biopsy obtaining 10-16 cores.
• ≤15mm diameter of qualifying lesion as measure by greatest diameter
• Subject is willing and able to adhere to specific protocol visits and required testing throughout study
• A single MRI region of suspicion (PI-RADS assessment of 3 or 4) with a minimum of 2 targeted cores obtained and at least one confirming GGG2 disease on biopsy (lesion may cross the mid-line). 
• <34% of the systemic biopsy cores are positive for GGG1 and GGG2, non-systemic (mpMRI targeted) biopsy cores are excluded from this calculation. 
• Documentation containing the tracking of all systematic and targeted cores using the targeted biopsy system’s 3D registration software. All cores must be submitted and processed to allow correlation of core location to the system’s 3D registration software.
• Exclusion: All MRI Central Imaging confirmed by PI-RADS 4 lesions negative on biopsy, Any prior surgery, intervention, or minimally invasive therapy, (MIST) for the prostate cancer or bladder neck, Previous treatment for genital cancer, Active urinary tract infection, Active or clinically chronic prostatitis or granulomatous prostatitis, Any rectal pathology, anomaly or previous treatment that could change properties of rectal wall or insertion and use of TRUS, Any cognitive or psychiatric condition that interferes with or precludes direct and accurate communication with the study Investigator regarding the study or affects the ability to complete the study quality of life questionnaires, No positive >GG2 cores known to be outside of the targeted treatment area (lesion plus 1 cm margin). GGG1 acceptable, Evidence of extracapsular extension of cancer (MRI read as “definite”, “frank” or “gross” ECE) as determined by MRI central Imaging, Contraindications to MRI and Subjects with an installed pacemaker or other potentially electrically conductive implants (e.g. ICD, drug infusion pump, neurostimulator and bladder stimulators) implanted within 200mm (8 inches) of the Vanquish procedure Field Generator. Implants that are within 200 mm (8 inches) and can be turned off for the duration of the study procedure are acceptable.

Mitchell C. Fraiman, MD

Testing the addition of radiation therapy to the usual immune therapy treatment (atezolizumab) for patients with extensive stage small cell lung cancer (NRG-LU007: Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial)

Testing the addition of high dose, targeted radiation to the usual treatment for locally advanced inoperable non-small cell lung cancer (nrg-lu008, phase iii prospective randomized trial of primary lung tumor stereotactic body radiation therapy followed by concurrent mediastinal chemoradiation for locally advanced non-small cell lung cancer), two studies for patients with high-risk prostate cancer testing less intense treatment for patients with a low gene risk score and testing a more intense treatment for patients with a high gene risk score, the predict-rt trial  (nrg-gu-009: parallel phase iii randomized trials for high-risk prostate cancer evaluating de-intensification for lower genomic risk and intensification of concurrent therapy for higher genomic risk with radiation), two studies for patients with unfavorable intermediate risk prostate cancer testing less intense treatment for patients with a low gene risk score and testing a more intense treatment for patients with a higher gene risk score (nrg-gu010: parallel phase iii randomized trials of genomic-risk stratified unfavorable intermediate risk prostate cancer: de-intensification and intensification clinical trial evaluation (guidance), comparing observation versus radiation for newly diagnosed grade ii meningiomas that have been completely removed through surgery (nrg-bn003. phase iii trial of observation versus irradiation for a gross totally resected grade ii meningioma), the phase iii 'high five trial' five fraction radiation for high-risk prostate cancer, a pragmatic randomized phase iii trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery [erasur].

• Diagnosis of extensive stage small cell lung cancer
• Partial response or stable response after 4-6 cycles of etoposide/platinum (E/P) doublet plus atezolizumab  
• Must have measurable disease and 3 or fewer observable liver metastases and no evidence of progressive disease (per RECIST)

ClinicalTrials.gov | NCT04402788

Aviva Berkowitz, MD

[email protected]

• Diagnosis of stage II or III non-small cell lung cancer (NSCLC) with known PD-L1 status 
• Must have an identified primary tumor and at least one nodal metastasis 
• Up to 4 cycles of systemic therapy received prior to registration is allowable; any prior chemotherapy for a different cancer is also permissible
• No evidence of distance metastases based on FDG PET/CT scan

ClinicalTrials.gov | NCT05624996

• Subject is at least 18 years of age 
• Diagnosis of High-risk adenocarcinoma of prostate cancer (PSA>20ng/mL or cT3a-T4 or Gleason Score 8-10 or Node positive)
• Is not metastatic disease outside of the pelvic nodes (M1a, M1b, or M1c) on imaging
• No Prior systemic chemotherapy within 3 years and No prior radiotherapy to the region of the study cancer

ClinicalTrials.gov | NCT04513717

Mark Hurwitz, MD

• Diagnosis of intermediate-risk adenocarcinoma of prostate cancer (PSA 10-20 ng/mL or stage T2b-c or Gleason Score 7) 
• No previous radical surgery (prostatectomy) or any form of curative-intent ablation for prostatic cancer 
• No prior hormonal therapy and No prior radiotherapy to the prostate/pelvis region

ClinicalTrials.gov | NCT05050084

• Diagnosis of unifocal intracranial meningioma, gross totally resected, and histologically confirmed as WHO grade II 
• Is not optic nerve sheath meningioma, spinal or other extracranial meningioma, multiple meningiomas, hemangiopericytoma, or metastatic meningioma 
• No prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of three years

ClinicalTrials.gov | NCT03180268

Keith Meritz, MD

• Male at least 18 years of age
• Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the primary outcome are eligible for this trial
• Men who are sexually active should be willing and able to use medically acceptable forms of contraception during treatment and for 90 days after end of Radiation Therapy
• Pathologically (histologically or cytologically) proven diagnosis of adenocarcinoma of prostate cancer
• No prior radical prostatectomy

ClinicalTrials.gov | NCT05946213

• Male or female ≥ 18 years
• Histologically-confirmed metastatic colorectal adenocarcinoma
• No known microsatellite instable (MSI) tumor
• No known BRAF V600E mutation
• Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression. No known peritoneal and/or omental metastases. If radiologic studies suggest the presence of peritoneal disease, a diagnostic laparoscopy is recommended to verify the absence of peritoneal implants
• Primary tumor is already resected OR primary tumor is surgically amenable to resection, as determined by consultation and documentation with surgeon or documentation of discussion in the institutional multi-disciplinary tumor board where a surgeon confirms resectability. Patients with unresectable primary tumors are not eligible
• Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
• Patients must have no overt evidence of disease progression during systemic therapy prior to registration
• Patients must be receiving (or have received) first-line systemic therapy for metastatic disease for a minimum of 16 weeks and a maximum of 26weeks
• For women of childbearing potential only, a negative pregnancy test done ≤ 14 days prior to registration is required
• Transplantation (HCT) Recipients with Sinusoidal Obstructive Syndrome (SOS) Post-HCT Associated with either Renal and/or Pulmonary Dysfunction with Either Refractory or Progressive Disease Following Defibrotide Therapy”

“A Phase II Intrapatient Open-Label Dose Escalation Trial of Defibrotide in Hematopoietic Cell Transplantation (HCT) Recipients with Sinusoidal Obstructive Syndrome (SOS) Post-HCT Associated with either Renal and/or Pulmonary Dysfunction with Either Refractory or Progressive Disease Following Defibrotide Therapy”

• Male or female, Age 1 month - 75 years
• HCT recipients (Auto or Allograft)
• SOS/VOD as defined by Cairo/Cooke Diagnostic criteria (1) (Table 3) with either renal and/or pulmonary dysfunction as defined by Cairo/Cooke Grading criteria (1) (Appendix I)
• Patients with SOS/VOD failing to obtain a complete response (CR) defined by Grade I or less by Cairo/Cooke Grading criteria (1) (Appendix I). This would therefore include patients with stable disease after at least 14 days of defibrotide or partial response after at least 21 days of defibrotide (25mg/kg/day).
• Progressive disease defined by progression of at least one grade or more from diagnostic grade as defined by Cairo/Cooke Grading criteria (1) (Appendix I) following at least 7 days of defibrotide (25mg/kg/day).
• Exclusion Criteria
• Patients who did not receive HCT
• Concomitant systemic anticoagulation (excluding central venous line management, fibrinolytic instillation for central venous line occlusion, management of intermittent dialysis or ultrafiltration of CVVH)
• Active bleeding and/or hemorrhage of at least grade 2 and above
• History of development of Grade III/IV anaphylaxis probably or directly secondary to defibrotide
• Female patients who are pregnant or breast feeding

ClinicalTrials.gov | NCT05987124

• Coronavirus Updates
• Education at MUSC
• Adult Patient Care
• Children's Health
• Hollings Cancer Center
• Research at MUSC
• MUSC Catalyst News
• Prolongin T cell survival

Improving cancer immunotherapy by prolonging T-cell survival

In the past decade, immunotherapy has emerged as the fourth pillar of cancer treatment, joining surgery, radiotherapy and chemotherapy. It is an approved treatment in 15 cancers, including melanoma and some types of lymphomas and leukemias, but it is not effective in all cancers or in all patients.

Immunotherapy uses a patient’s own cancer-fighting cells, or T-cells, and adapts them so that they do a better job at killing cancer cells. T-cells are excellent at identifying and attacking tumor cells but can become exhausted in the tumor microenvironment, where they can become overworked and overstimulated and are starved of glucose and other nutrients by tumor cells. Helping these cells to function better and live longer could improve immunotherapy responses.

“T-cell exhaustion has been a key factor in preventing optimal responses to immunotherapy,” said Shikhar Mehrotra, Ph.D. co-leader of the Cancer Biology & Immunology Research Program and scientific director of the  Center for Cellular Therapy at MUSC Hollings Cancer Center.

Research in the Mehrotra Lab suggests that overcoming T-cell exhaustion could improve responses to two types of immunotherapies – anti-PD1 therapy and CAR-T therapy.

In a recent study reported in the Proceedings of the National Academies of Science , Mehrotra and his team, which included Shilpak Chatterjee, Ph.D., showed that T-cell exhaustion limited the efficacy of anti-PD1 therapy. That therapy works by unmasking tumor cells, allowing T-cells to see and target them.

The study showed that T-cells expressing the cell receptor CD38 were more susceptible to exhaustion. Using an anti-CD38 antibody, the research team was able to block CD38 and overcome T-cell exhaustion. They then showed in a mouse model that overcoming T-cell exhaustion by blocking CD38 restored the efficacy of anti-PD1 therapy against cancer. However, the anti-CD38 antibody they used in the mouse model would not be appropriate for use in humans.

To find a way to combat T-cell exhaustion in humans, and specifically for CAR-T therapy, Mehrotra and Chatterjee have developed and patented a cytokine “cocktail” that can be used to reduce CD38 expression on T-cells. In CAR-T therapy, the patient’s own immune cells are harvested, enhanced to detect and fight the cancer cells more effectively and then put back into the patient. 

Although the processing of these cells outside the body makes them better able to fight cancer, it also exhausts them, making it difficult for them to survive long in the nutrient-depleted tumor microenvironment. Treating the cells with the cytokine cocktail while they are out of the body not only reduces their expression of CD38, a marker of exhaustion, but it also helps to ensure their function and longevity by giving them the traits of both Th1 (effector) and Th17 (stemness) cells.

"In the clinical setting, we want these T-cells to be ‘marathon runners,’ not sprinters in a 100-meter dash.” -- Dr. Shikhar Mehrotra

Th1 cells can mount an anti-cancer response but are short-lived, while Th17 cells have greater longevity but are unable to mount a response. Combining the two harnesses the strengths of both, producing T-cells that live longer and can mount an effective response. These cells are also less likely to depend on glucose and better able to withstand the nutrient-deprived tumor microenvironment.

Mehrotra believes that the cocktail could be an important key to overcoming exhaustion in T-cells, ensuring their long-term effectiveness and improving responses to immunotherapy.

“In the clinical setting, we want these T-cells to be ‘marathon runners,’ not sprinters in a 100-meter dash,” said Mehrotra.  

The cocktail is currently being used in a phase 1 clinical trial of CD19 CAR-T-cells in adult patients with certain relapsed or refractory B-cell cancers (ClinicalTrials.gov Identifier: NCT05702853 ). It allows the cells to continue dividing and remain persistent as they attack the tumor environment. 

Thus far, two patients have been enrolled and both have tolerated the treatment well and achieved complete responses without experiencing any of the side effects that are otherwise commonly associated with CAR-T-cell therapy. Based on these results, a second set of patients is being enrolled in this trial, which is now open at MUSC’s Hollings Cancer Center.

Kar A, Ghosh P, Gautam A, Chowdhury Sasak D, Sarkar I, Bhoumik A, Barman S, Chakraborty P, Mukhopadhyay A, Mehrotra S, Ganesan SK, Paul S, Chatterjee S. CD38-RyR2 axis-mediated signaling impedes CD8 +  T cell response to anti-PD1 therapy in cancer. Proc Natl Acad Sci U S A. 2024 Mar 12;121(11):e2315989121. doi: 10.1073/pnas.2315989121. Epub 2024 Mar 7. PMID: 38451948; PMCID: PMC10945783.

About the Author

Sarah Allen Sarah Allen is a Master's student at MUSC and a science communications intern in the College of Graduate Studies.

Categories: Cancer , Research

Cancer Research Data Exchange Summit (Venue)

NCI Shady Grove is located at  9609 Medical Center Drive, Rockville, MD 20850.

This location is easily accessible by both car and public transportation.

Arriving from the  south  of Rockville using Route 270, take exit 8 toward Shady Grove Road. Keep left on the exit ramp, and at the end of the ramp, turn left at the light onto Shady Grove Road heading west. Get into the right lane, and turn right onto Key West Avenue (MD 28 W). Turn left at the next light onto Medical Center Drive. From there, turn right onto Blackwell Road and turn right again into the NCI employee parking garage. Visitors can have their parking ticket validated at the guard station inside the main lobby.

Arriving from the  north  of Rockville using Route 270, take exit 8 and keep right to take the Omega Drive ramp. The ramp will bring you to a stop sign. Turn left and continue on Omega Drive, which turns into Medical Center Drive. From Medical Center Drive, turn right onto Blackwell Road and turn right again into the NCI employee parking garage. Visitors can have their parking ticket validated at the guard station inside the main lobby.

People driving to NCI Shady Grove should use the parking garage that is directly across the circle from the NCI building. Parking tickets can be validated at the guard station in the lobby after a visitor has signed in.

Area Restaurants

• The Downtown Crown
• Falls Grove Village Center

Hotel Accommodations

Attendees are responsible for arranging and reserving their travel, including transportation and hotel accommodations. Please find a list of recommended hotels near NCI Shady Grove.

• Address : 204 Boardwalk Pl, Gaithersburg, MD 20878
• Walk for 13 ft.
• Head southwest toward Boardwalk Pl (36 ft)
• Turn left onto Boardwalk Pl (285 ft)
• Turn right, take the stairs (0.1 mi)
• Slight right toward Washingtonian Blvd, take the stairs (105 ft)
• Slight left toward Washingtonian Blvd (39 ft)
• Turn right toward Washingtonian Blvd (384 ft)
• Turn left onto Washingtonian Blvd (0.3 mi)
• Turn left onto Fields Rd (423 ft)
• Continue onto Omega Dr (0.4 mi)
• Continue straight to stay on Omega Dr (177 ft)
• Continue onto Medical Center Dr (0.1 mi)
• Turn right; the destination (9609 Medical Center Dr, Rockville, MD 20850) will be on the right (249 ft).
• Address : 9751 Washingtonian Blvd, Gaithersburg, MD 20878
• Head south toward Washingtonian Blvd (0.1 mi)

Other Hotel Options:

• Hilton Garden Inn Rockville-Gaithersburg: 10-minute walk (0.5 mile) to NCI Shady Grove.
• Homewood Suites by Hilton Rockville-Gaithersburg: 10-minute walk (0.5 mile) to NCI Shady Grove.
• Courtyard by Marriott Rockville: 12-minute walk (0.6 mile) to NCI Shady Grove.
• SpringHill Suites by Marriott Gaithersburg: 18-minute walk (0.8 mile) to NCI Shady Grove.

Shuttle Service:

• NCI Shady Grove offers free shuttle loops to the NIH Main Campus and Shady Grove Metro Station, equipped with bike racks.
• The NCI Shady Grove Metro Shuttle begins at 6:00 a.m. on the west side of the Shady Grove metro station. View the metro shuttle schedule .
• The NCI Shady Grove Express begins at 7:15 a.m., going from NCI to Building 31. View the NCI Express shuttle schedule .
• To ride the shuttle, employees must show proper NIH badge identification, while visitors need to secure a shuttle pass from their sponsor. The Shuttle Pass Request Form is available online.
• All items found on shuttles are returned to Shady Grove, suite TE200.

COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

Student Research Worker

• Radiation Oncology
• Columbia University Medical Center
• Opening on: Apr 18 2024
• Job Type: Short Term Casual
• Bargaining Unit:
• Regular/Temporary: Temporary
• End Date if Temporary: 09/01/2024
• Hours Per Week: 20
• Standard Work Schedule:
• Building: Medical Center
• Salary Range: $22.00 - $22.00

Position Summary

The Department of Radiation Oncology are looking for a summer intern student to join a dynamic team of data scientists and clinicians to develop advanced AI solutions for medical image segmentation within the context of adaptive radiotherapy. 

Responsibilities

• Harmonizing CT image data
• Work on new segmentation models
• Contribute to building an AI-driven interactive medical image segmentation pipeline

Minimum Qualifications

• Current undergraduate obtaining a bachelor's degree in medical physics, biomedical engineering, electrical engineering, computer science or other data science related fields; in 3rd or 4th Year.
• High school Graduate or Equivalency required.
• Familiar with Python, JavaScript/HTML/CSS and WebGL.
• Experience with medical image analysis, PyTorch, ITK, and MONAI

Preferred Qualifications

• Master's degree or equivalent in education and experience.

Equal Opportunity Employer / Disability / Veteran

Columbia University is committed to the hiring of qualified local residents.

Commitment to Diversity 

Columbia university is dedicated to increasing diversity in its workforce, its student body, and its educational programs. achieving continued academic excellence and creating a vibrant university community require nothing less. in fulfilling its mission to advance diversity at the university, columbia seeks to hire, retain, and promote exceptionally talented individuals from diverse backgrounds.  , share this job.

Thank you - we'll send an email shortly.

Other Recently Posted Jobs

Director-Faculty Programs & Services

Program coordinator, health education manager.

Refer someone to this job

• ©2022 Columbia University
• Accessibility
• Administrator Log in

Wait! Before you go, are you interested in a career at Columbia University? Sign up here! 

Thank you, for sharing your information. A member of our team will reach out to you soon!

This website uses cookies as well as similar tools and technologies to understand visitors' experiences. By continuing to use this website, you consent to Columbia University's usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice .

News Center

Feinberg investigators lead aha heart disease research initiative.

Feinberg investigators have been selected to lead a $15 million American Heart Association research initiative studying the role of inflammation in heart disease. 

Matt Feinstein, ‘11 MD, ‘17 MS , associate professor of Medicine in the Division of Cardiology , will direct one of three centers in the country funded by the American Heart Association’s Strategically Focused Research Network (SFRN) on Inflammation in Cardiac and Neurovascular Disease, which will focus on understanding inflammatory responses and how to treat heart disease caused by inflammation.  

The American Heart Association funds Strategically Focused Research Networks as part of its mission to advance cardiovascular health for all. Research teams apply for the program’s four-year grants with novel and innovative ideas to better understand cardiovascular diseases impacted by each research network’s focus, the latest of which is inflammation.  

While inflammation is critical for mounting immune responses against pathogens or injuries, inflammatory dysregulation can fuel numerous diseases, including in the heart. 

Research teams at Feinberg will undertake three different projects focused on inflammation in heart failure with preserved ejection fraction.  

Heart failure with preserved ejection fraction, or HFpEF, is marked by excessive inflammation and accounts for more than half of all heart failure cases in the U.S. The condition also carries a significant public health burden: 50 percent of people diagnosed with HFpEF die within five years, according to the American Heart Association.  

The research initiatives will focus on immune cells, which regulate inflammation in the body, and how the cells are affected by stressors. Investigators will also analyze existing and novel approaches to modulating metabolism and immune cell responses in HFpEF with the ultimate goal of targeting inflammation to address the disease.  

“We’re focusing on how inflammation gets turned on and off; fundamentally, immune cells are key for this,” Feinstein said. “But why do some people experience unresolving inflammation and others don’t? And how does this make some especially prone to progressive cardiometabolic disease and HFpEF? Our goal is to answer these critical questions. We’ll do this by bringing together patient-centered approaches and experimental model systems, all coalescing around the question of what’s turning inflammation on and off in the setting of cardiometabolic risk factors and HFpEF. The goal is that this knowledge will inform approaches that modulate harmful, unresolving inflammation to curb cardiometabolic disease and HFpEF.” 

Additional Feinberg faculty serving as principal investigators on projects in the Feinberg-based center include Sanjiv Shah, ’00 MD, the Neil J. Stone, MD, Professor of Medicine in the Division of Cardiology, Edward Thorp, PhD, the Frederick Robert Zeit Professor of Pathology , and Kiarri Kershaw, PhD, MPH ,  associate professor of Preventive Medicine in the Division of Epidemiology . 

Christopher Botanga, PhD, professor of biology and principal investigator at Chicago State University (CSU) will serve as director of training phase synergy. This collaboration will increase the pipeline of opportunities — which includes the NUCATS supported Science Immersion Program — for CSU students to collaborate on specific projects as well as have near-peer mentoring from SFRN postdoctoral fellows. Obayed Raihan, assistant professor of Pharmaceutical Sciences at CSU, will help lead the project’s bioinformatics consortium, which will engage in shared methods development work on using bioinformatic approaches to understand immune-inflammatory contributors to cardiovascular disease.

Other research teams selected as part of the network included investigators at the University of Pittsburgh and the University of Michigan.  

“We are grateful to the AHA and excited for the opportunity to answer fundamental questions about how inflammation is regulated in cardiometabolic disease and HFpEF.” Feinstein said. “Ultimately, we hope that this knowledge will inform viable inflammation-modulating approaches to prevent and treat human disease.” 

Related Posts

Cancer drug trial provides lessons for future, feinberg classmates reconnect and reminisce at alumni weekend 2024, prospective medical students visit northwestern for second look.

Comments are closed.

Type above and press Enter to search. Press Esc to cancel.

• MSKCC.org external-link
• Employee login
• Talent Community

Career Areas

• Saved Jobs (0)
• Jobs Search
• Equality, Diversity & Inclusion
• Innovation & Growth
• Our Culture
• Our Locations
• Experienced Professionals
• Administrative
• Advanced Practice Providers
• Allied Health
• Data Science & Engineering
• Digital Informatics & Technology Solutions
• Environmental Health & Safety
• Facilities Management
• Nurse Anesthetists
• Professionals
• Rehabillitation
• Support Services
• Other Career Areas
• Students & Graduates
• Ready To Work
• Anesthesiology & Critical Care
• Pathology & Laboratory Medicine
• Medical Physics
• Neurosurgery
• Psychiatry & Behavioral Sciences
• Search jobs
• 2024-77353 Clinical Research Coordinator - Hybrid

Clinical Research Coordinator - Hybrid

Department: Research - Clinical

Location: New York, NY

Salary: $25.65 - $38.42/hrly

Company overview

The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across MSK collaborate to conduct innovative translational and clinical research that is driving a revolution in our understanding of cancer as a disease and improving the ability to prevent, diagnose, and treat it. MSK is dedicated to training the next generation of scientists and clinicians, who go on to pursue our mission at MSK and around the globe. 

Please review important announcements about vaccination requirements and our upcoming EHR implementation by clicking here .

Important Note for MSK Employees:

Your Career Hub profile is submitted to the hiring team as your internal resume. Please be sure your profile is fully complete with your skills, relevant experience and education (if required). Click here  to learn more. Please note, this link is only accessible for MSK employees.  

Job details

As the world’s oldest and largest private cancer center, everything that we do is focused on changing the way that the world treats cancer. Research is integral to MSK mission and clinical trials help us discover better forms of patient care and treatment. Our extraordinary clinicians and scientists work together to drive innovation and tackle some of the greatest challenges of biomedical science!

We are seeking Clinical Research Coordinators to join us in the fight against cancer. In this role, you will work collaboratively as part of our research team focused on responsibilities related to managing clinical trials data. You will be a crucial member of our team as data is the key to our research, allowing us to continuously learn about the people and diseases we help treat.

https://youtu.be/9R7QoNfmm0w

We have exciting opportunities for  hybrid work (mix of onsite and remote work)!

• A good decision-maker, with shown success at making timely decisions.
• Able to hold yourself and others accountable to achieve goals and live up to commitments.
• An effective communicator, capable of determining how best to reach different audiences.
• Willing to take action and eager to embrace new opportunities and tough challenges.
• Resilient in recovering from setbacks and skilled at finding detours around obstacles.
• Passionate about medical terminology and science.
• Collect, abstract, and enter data for research projects, databases, and/or protocols (clinical trials). 
• Ensure data quality and integrity throughout the life of the study.
• Collaborate with  research and care teams across MSK regarding data input.
• Generate data reports and deliver to all vital parties on the progress of the research project, database, or protocol.
• Design and/or improve databases, data forms and tools (e.g. patient/human subject calendars, schedules, tracking logs) to facilitate patient consent and specimen collection as needed for assigned research projects.
• Ensure all appropriate Institutional, State, and Federal regulations throughout the study are followed.
• Coordinate clinical research protocols and serve as the main point of contact, if applicable
• Healthcare/research experience a plus
• Commitment for at least 2 years 

Are you ready to learn more about our Benefits?

Pay Range $25.65 - $38.42/h

Please click to find out more about MSK’s compensation philosophy.

Application Process

Complete an Online Application

Interview Process

Provide References

Extension of Job Offer

New Employee Orientation

Find out more

Clinical research coordinator, spanish fluency required, clinical research coordinator, bengali fluency required, medical writer, pcctc - remote.

Your next opportunity could be right here. 

Search Jobs and Apply Now